Obesity Medicine: Treatment-Lifestyle, Pharmacotherapy, and Metabolic Surgery
Core concepts
Treatment is staged and chronic. Lifestyle intervention (reduced-calorie diet, ≥150 min/week physical activity, behavioral support) underpins all care. Understand guideline thresholds: pharmacotherapy is generally considered at BMI ≥30, or ≥27 with a weight-related comorbidity; metabolic/bariatric surgery at BMI ≥40, or ≥35 with comorbidities (some guidelines use ≥30 with poorly controlled type 2 diabetes).
Know the pharmacologic classes and their mechanisms and key adverse effects: GLP-1 receptor agonists (semaglutide, liraglutide)-GI effects, gallbladder disease, pancreatitis caution; dual GIP/GLP-1 agonist tirzepatide; older agents (phentermine/topiramate, bupropion/naltrexone, orlistat). Recognize that several older sympathomimetic and combination agents have been withdrawn or restricted in various jurisdictions-know mechanisms, not marketing.
For surgery, distinguish restrictive (sleeve gastrectomy, adjustable band) from combined restrictive-malabsorptive (Roux-en-Y gastric bypass, biliopancreatic diversion). Anticipate nutritional deficiencies: iron, B12, folate, calcium/vitamin D, and fat-soluble vitamins after bypass. Expect ~25–30% total weight loss with modern procedures and remission of diabetes in a substantial fraction.
Traps
- Applying drug/surgery thresholds without checking comorbidity status.
- Ignoring contraindications (e.g., pregnancy, certain psychiatric conditions, MEN2/medullary thyroid carcinoma history for some agents-verify labeling).
- Forgetting micronutrient monitoring after malabsorptive surgery.
- Assuming lifestyle failure means treatment failure; obesity is chronic and relapsing.
Rule of thumb
Match intensity to risk: lifestyle for all; add pharmacotherapy when BMI and comorbidity thresholds are met; reserve surgery for the highest-risk patients and follow lifelong nutritional surveillance.
Worked example
BMI 38 with uncontrolled type 2 diabetes: qualifies for pharmacotherapy and should be evaluated for metabolic surgery given comorbidity-counsel on both, not sequentially withholding options.